DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Human Albumin Market 2016-2020" report to their offering.
The analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.
The demand for albumin is high in APAC in countries like India and China. Still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. Thus, the awareness programs conducted by organizations such as PPTA, which includes International Plasma Awareness Week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions.
Key vendors
- CSL Behring
- Grifols
- Baxalta
- Octapharma
- Kedrion
Other prominent vendors
- AADi
- Ablynx
- Albumedix
- Ampio Pharmaceuticals
- Azaya Therapeutics
- Beijing Tiantan
- Biotest
- Bristol-Myers Squibb
- Celgene
- ConjuChem
- GSK
- Hebei Changshan Biochem Pharma
- HiMedia Laboratories
- Hualan Biological Engineering
- InVittria
- MedxBio
- Merck
- Mitsubishi Tanabe Pharma
- NantBioScience
- Novo Nordisk
- Novozymes
- Shanghai RAAS Blood Products
- Sucampo Pharmaceuticals
- Teva Pharmaceuticals
- Thermo Fisher Scientific
- Tianjin SinoBiotech & Beijing Bio-Fortune
- Ventria Bioscience
- Yoshitomi Pharmaceutical
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Plasma therapeutics: An overview
Part 06: Global plasma therapeutics market
Part 07: Plasma fractionation market
Part 08: Albumin: An overview
Part 09: Pipeline portfolio
Part 10: Global albumin market
Part 11: Market landscape
Part 12: Market segmentation by application
Part 13: Geographical segmentation
Part 14: China albumin market
Part 15: Market drivers
Part 16: Impact of drivers
Part 17: Market challenges
Part 18: Impact of drivers and challenges
Part 19: Market trends
Part 20: Vendor landscape
Part 21: Appendix
For more information visit http://www.researchandmarkets.com/research/2xpnvt/global_human
